MedCognetics, a pioneer in artificial intelligence (AI) for breast cancer screening, has announced a strategic collaboration with Laurel Bridge Software, a leader in medical imaging workflow solutions. Together, the companies are delivering a comprehensive, end-to-end solution for screening and diagnostic mammography that enhances clinical efficiency, strengthens data security, and improves patient outcomes.

Announced during Breast Cancer Awareness Month, the collaboration underscores both organizations’ shared commitment to advancing women’s healthcare through secure and intelligent imaging innovations.

As AI becomes increasingly central to medical imaging, the U.S. Food and Drug Administration (FDA) emphasizes that trustworthy AI must meet three key criteria — clinical accuracy, seamless workflow integration, and robust data security. The partnership between MedCognetics and Laurel Bridge addresses this “trifecta” through a solution that not only delivers exceptional diagnostic performance but also integrates securely and efficiently within existing clinical infrastructures.

MedCognetics has established itself as a leader in developing unbiased, reliable AI solutions for breast imaging. Its technology is designed to enhance clinical confidence by reducing diagnostic variability and improving early detection of breast cancer. With support from Laurel Bridge Software, MedCognetics’ AI integrates effortlessly into radiology workflows, maintaining both speed and security.

During MedCognetics’ FDA 510(k) clearance process, Laurel Bridge’s Compass Routing Workflow Manager played a key role in providing the robust infrastructure and compliance required to meet stringent regulatory standards. The Compass platform also supports MedCognetics’ mobile breast imaging initiative, which extends vital screening access to higher-risk and underserved populations.

Laurel Bridge’s Compass platform offers a flexible, secure system for efficient image routing and results management. It safeguards patient privacy through automated de-identification of metadata before AI processing and re-identification upon completion, ensuring accurate attachment to patient records. The solution also facilitates secure data exchange without the need for VPNs—streamlining infrastructure management and minimizing cybersecurity risks.

By combining MedCognetics’ advanced AI with Laurel Bridge’s proven workflow orchestration, healthcare organizations gain a scalable and secure solution to deploy AI in clinical practice confidently. This collaboration represents a milestone in the evolution of breast cancer diagnostics—delivering precision, efficiency, and patient-centered innovation in one integrated platform.

“We believe that for AI to truly change healthcare, it must be trustworthy and easy to integrate,” said Jeff Blair, President of Laurel Bridge Software. “Our collaboration with MedCognetics demonstrates how a complete solution can address not just clinical accuracy but also workflow efficiency and data security.”

“The FDA’s guidance on AI reinforces what we’ve known all along — that a great algorithm is only part of the story,” added Ron Nag, CEO of MedCognetics. “Laurel Bridge’s technology provides the workflow and privacy framework needed to ensure our solution is both effective and secure, supporting our mission to advance breast screening and diagnosis worldwide.”